Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

12 Pages (Click to Jump) V  < 1 2 3 4 5 > »    
 
  
Reply to this topic

CGS, COGSTATE LTD
mayo1975
post Posted: Nov 22 2007, 11:03 AM
  Quote Post


Posts: 37




Hello All,

I'm not sure who follows CGS, but I just bought into the stock, based on the excellent announcement published:




CogState Ltd
ABN 80 090 975 723
Level 7
21 Victoria Street
Melbourne Vic 3000
Australia
Page 1 of 2
ASX Announcement
Melbourne, 22 November 2007
CogState Signs Agreement for Phase IIb Schizophrenia Trial
Key points:
 CogState tests will be used to objectively measure cognition as an endpoint in a Phase
IIb Schizophrenia trial run by an international pharmaceutical company
 Study to be run in multiple European and South American sites, in multiple languages
 CogState was selected after a competitive tender process
 The contract will generate gross revenue in excess of A$0.7m for CogState over the
course of the trial (approx. 2 years)
CogState Ltd (ASX:CGS) announced today that it has signed an agreement with an international
pharmaceutical company for the use of CogState’s cognitive testing technology, and associated
services, in a Phase IIb trial to be conducted at a large number of sites throughout Europe and South
America. The trial will investigate the benefits of a new therapy for schizophrenia against a leading
antipsychotic drug.
One of the key criteria for selection of cognitive service provider was the ability to manage a trial across
a large number of sites, countries and languages. CogState’s advanced, real time data management
systems were viewed as capable of providing the high level of study site support and data monitoring &
management required for an international, multicentre trial.
Mr Brad O’Connor, Chief Executive Officer of CogState, said: “It is pleasing to see our customers
acknowledging our cognitive test solution and data management systems as the best in the industry for
collection, tracking and management of cognitive data in their trials. CogState’s real time data
management systems mean that we are well placed to manage the data collected in multi-centre
studies, conducted anywhere in the world.”
Mr O’Connor added: “This contract is the tenth contract since 1 July 2007. Including the contract
announced today, the collective value of contracts signed since 1 July 2007 is A$2 million.”
About CogState
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of
cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food
companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.
Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations
including Pfizer, Merck, Lundbeck, GlaxoSmithKline, AstraZeneca, Centres for Disease Control (USA), ALZA
Corporation (a member of the Johnson and Johnson group), and Organon USA. CogState is currently expanding
its existing activities in the US and European clinical trial markets.

 
oracle
post Posted: Jan 17 2007, 08:57 AM
  Quote Post


Posts: 787
Thanks: 21


In reply to: theadder on Tuesday 16/01/07 04:28pm

Nice pick-up eddy.

Cheers



--------------------
oracle
 
theadder
post Posted: Jan 16 2007, 04:28 PM
  Quote Post


Posts: 5,264
Thanks: 1136


From the USPTO today..

http://patft1.uspto.gov/netacgi/nph-Parser...116+AND+ACN/AU)

United States Patent 7,163,513

Darby , et al.

January 16, 2007

Psychological testing method and apparatus

Abstract
A method for psychological testing of a subject is performed by (A) presenting a test by means of a testing means having output means (e.g. a computer monitor) and input means (e.g. a keyboard); and, (B) instructing the subject by displaying a simulation (as shown in the figure) of the test by means of the output means so that the subject can learn how to perform the test from the simulation. The test is therefore independent of the subject's language skills, or of verbal instructions provided by a supervisor.


--------------------------------------------------------------------------------
Inventors: Darby; David (Melbourne, AU), Bush; Ashley (Somerville, MA)

Assignee: Cogstate, Ltd. (Victoria, AU)



 
oracle
post Posted: Dec 29 2006, 10:34 AM
  Quote Post


Posts: 787
Thanks: 21


Bulls seem to be slowly wresting control back from the bears.

All of a sudden the chart doesn't look half bad...



--------------------
oracle
 
oracle
post Posted: Dec 12 2006, 05:57 PM
  Quote Post


Posts: 787
Thanks: 21


CGS came 12th in the Deloitte Technology Fast50 for 2006.

It's noted on the website but wasn't announced to the market - probably just as well as an appearance in this list has often been the kiss of death in the following year - here's hoping CGS bucks the trend. Then again there hasn't exactly been a deluge of good news lately - you reckon they might have been tempted to give it a fly.

Cheers



--------------------
oracle
 
oracle
post Posted: Dec 7 2006, 02:50 PM
  Quote Post


Posts: 787
Thanks: 21


In reply to: dekay23 on Wednesday 06/12/06 03:45pm

QUOTE
I am still quite positive about the company


...seems the directors are too dave. More buying.

A nod's as good as a wink.

Cheers



--------------------
oracle
 


dekay23
post Posted: Dec 6 2006, 03:45 PM
  Quote Post


Posts: 3


In reply to: oracle on Wednesday 06/12/06 02:49pm

I hope so too Oracle (I am still quite positive about the company).
Cheers,
Dave

 
oracle
post Posted: Dec 6 2006, 02:49 PM
  Quote Post


Posts: 787
Thanks: 21


Wee bit more interest back in CGS today.

Hopefully the quarterly growth is back on track and we should know more about the Neuro-CRC bid before Christmas.

Cheers



--------------------
oracle
 
oracle
post Posted: Nov 28 2006, 01:32 PM
  Quote Post


Posts: 787
Thanks: 21


In reply to: dekay23 on Monday 27/11/06 08:48pm

Cheers dave,

QUOTE
I wonder if there is real earnings potential outside of cognition testing for clinical drug trials?


Yep that's the biggie alright. I remain to be convinced but we should get some indication over the next 12 mths. In the meantime I am comfortable with the growth prospects in CNS trials. Its by no means a huge market but there is plenty of room to move for a company the size of CGS.

Totally agree that it's nonsense for them to trumpet about how big CNS drug sales are forecast to be.

A few things bug me about this stock but I am still prepared to believe the story.

Cheers



--------------------
oracle
 
dekay23
post Posted: Nov 27 2006, 08:48 PM
  Quote Post


Posts: 3


In reply to: oracle on Monday 27/11/06 11:38am

Yep - supports the 'these quarterly results are a mere timing blip' comments made at the AGM - a variety of good news possible and Mr Myer's purchases should ensure no bad news in the short term.

I wonder if there is real earnings potential outside of cognition testing for clinical drug trials? It's fine to talk about a market of $70 billion for CNS drugs, but how much of that translates into $$$ for testing cognition during drug trials?

Cheers,
Dave

 
 


12 Pages (Click to Jump) V  < 1 2 3 4 5 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING